Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4% - Time to Sell?

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock price traded down 4% on Tuesday . The company traded as low as $17.60 and last traded at $17.75. 19,174 shares traded hands during trading, a decline of 87% from the average session volume of 151,377 shares. The stock had previously closed at $18.49.

Rapport Therapeutics Stock Performance

The firm has a 50-day moving average price of $21.90.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of RAPP. Charles Schwab Investment Management Inc. acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth approximately $1,498,000. Millennium Management LLC acquired a new stake in Rapport Therapeutics in the second quarter worth $2,716,000. Perceptive Advisors LLC bought a new stake in Rapport Therapeutics in the second quarter valued at $17,403,000. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the second quarter valued at $86,730,000. Finally, TD Asset Management Inc bought a new position in shares of Rapport Therapeutics during the second quarter worth about $2,361,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.